Resveratrol as adjunctive therapy in treatment of irritability in children with autism: A double-blind and placebo-controlled randomized trial.
Fatemeh HendoueiHossein Sanjari MoghaddamMohammad Reza MohammadiNegin TaslimiFarzin RezaeiShahin AkhondzadehPublished in: Journal of clinical pharmacy and therapeutics (2019)
This clinical trial demonstrated no significant effect for adjunctive treatment with resveratrol on irritability of patients with ASD. However, it provided preliminary evidence indicating that resveratrol could improve hyperactivity/non-compliance of ASD patients.
Keyphrases
- autism spectrum disorder
- clinical trial
- end stage renal disease
- intellectual disability
- attention deficit hyperactivity disorder
- chronic kidney disease
- newly diagnosed
- squamous cell carcinoma
- randomized controlled trial
- prognostic factors
- study protocol
- stem cells
- phase ii
- radiation therapy
- combination therapy
- open label
- replacement therapy